Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood

Cytotherapy

Volumn 17, Issue 1, 2015, Pages 86-97

  Zhang, Zhen ^a   Zhao, Xianlan ^a   Zhang, Tengfei ^a   Wang, Liping ^a   Yang, Lingzhu ^a   Huang, Lan ^a   Li, Feng ^a   Liu, Jinyan ^a   Yue, Dongli ^a   Wang, Fei ^a   Li, Jieyao ^a   Guan, Fangxia ^a   Xu, Yuming ^a   Zhang, Bin ^a,b   Zhang, Yi ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer; Cord blood; Cytokine induced killer cells; Peripheral blood

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DEGRANULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR XENOGRAFT; UMBILICAL CORD BLOOD; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CYTOLOGY; CYTOTOXICITY; FETUS BLOOD; IMMUNOLOGY; NEOPLASM; NUDE MOUSE; PHENOTYPE; PHYSIOLOGY; UMBILICAL CORD;

MUS MUSCULUS;

ANIMALS; APOPTOSIS; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FETAL BLOOD; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PHENOTYPE; UMBILICAL CORD;

EID: 84927125715     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.09.006     Document Type: Article

References (50)

1. Yee C. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?. Clin Cancer Res 2013, 19:4550-4552.
2. Thanendrarajan S., Kim Y., Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012, 12:565-572.
3. Rosenberg S.A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 2011, 8:577-585.
4. Pereira M.I., Paiva A. Dendritic cells in cord blood transplantation: a review. Stem Cells Int 2011, 2011:539896.
5. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
6. Lang P.A., Lang K.S., Xu H.C., Grusdat M., Parish I.A., Recher M., et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A 2012, 109:1210-1215.
7. Levy E.M., Roberti M.P., Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. JBiomed Biotechnol 2011, 2011:676198.
8. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
9. Wei C., Wang W., Pang W., Meng M., Jiang L., Xue S., et al. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma. Tumour Biol 2013, 35:1997-2007.
10. Wu C., Jiang J., Shi L., Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008, 28:3997-4002.
11. Huang J., Li C., Wang Y., Lv H., Guo Y., Dai H., et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol 2013, 149:156-168.
12. Du X., Jin R., Ning N., Li L., Wang Q., Liang W., et al. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep 2012, 28:1743-1749.
13. Mesiano G., Todorovic M., Gammaitoni L., Leuci V., Giraudo Diego L., Carnevale-Schianca F., et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 2012, 12:673-684.
14. Helms M.W., Prescher J.A., Cao Y.A., Schaffert S., Contag C.H. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010, 59:1325-1334.
15. Rettinger E., Meyer V., Kreyenberg H., Volk A., Kuci S., Willasch A., et al. Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models. Front Oncol 2012, 2:32.
16. Wang X.P., Xu M., Gao H.F., Zhao J.F., Xu K.C. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma. World J Gastroenterol 2013, 19:2956-2962.
17. Liu L., Zhang W., Qi X., Li H., Yu J., Wei S., et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012, 18:1751-1759.
18. Gammaitoni L., Giraudo L., Leuci V., Todorovic M., Mesiano G., Picciotto F., et al. Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res 2013, 19:4347-4358.
19. Todorovic M., Mesiano G., Gammaitoni L., Leuci V., Giraudo Diego L., Cammarata C., et al. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. JImmunother 2012, 35:579-586.
20. Nishimura R., Baker J., Beilhack A., Zeiser R., Olson J.A., Sega E.I., et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008, 112:2563-2574.
21. Li Y., Schmidt-Wolf I.G., Wu Y.F., Huang S.L., Wei J., Fang J., et al. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res 2010, 30:3493-3499.
22. Durrieu L., Lemieux W., Dieng M.M., Fontaine F., Duval M., Le Deist F., et al. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines. Cytotherapy 2014, 16:845-856.
23. Introna M., Franceschetti M., Ciocca A., Borleri G., Conti E., Golay J., et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006, 38:621-627.
24. Durrieu L., Gregoire-Gauthier J., Dieng M.M., Fontaine F., le Deist F., Haddad E. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. Cytotherapy 2012, 14:1245-1257.
25. Introna M., Borleri G., Conti E., Franceschetti M., Barbui A.M., Broady R., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959.
26. Germenis A.E., Karanikas V. Cord blood as a source of non-senescent lymphocytes for tumor immunotherapy. JReprod Immunol 2010, 85:47-50.
27. Niu Q., Wang W., Li Y., Qin S., Wang Y., Wan G., et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 2011, 11:449-456.
28. Shah N., Martin-Antonio B., Yang H., Ku S., Lee D.A., Cooper L.J., et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013, 8:e76781.
29. Moschella F., Valentini M., Arico E., Macchia I., Sestili P., D'Urso M.T., et al. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res 2011, 71:3528-3539.
30. Strazza M., Azoulay-Alfaguter I., Pedoeem A., Mor A. Static adhesion assay for the study of integrin activation in T lymphocytes. JVis Exp 2014.
31. Zlotnik A., Yoshie O. The chemokine superfamily revisited. Immunity 2012, 36:705-716.
32. Kirshberg S., Izhar U., Amir G., Demma J., Vernea F., Beider K., et al. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS One 2011, 6:e24856.
33. Vicinus B., Rubie C., Stegmaier N., Frick V.O., Kolsch K., Kauffels A., et al. miR-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: Significance of their regulation. Oncol Rep 2013, 30:1285-1292.
34. Tang Y., Li X., Wang M., Zou Q., Zhao S., Sun B., et al. Increased numbers of NK cells, NKT-like cells, and NK inhibitory receptors in peripheral blood of patients with chronic obstructive pulmonary disease. Clin Dev Immunol 2013, 2013:721782.
35. Ma Y., Xu Y.C., Tang L., Zhang Z., Wang J., Wang H.X. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 2012, 1:11.
36. Zhang J., Zhu L., Wei J., Liu L., Yin Y., Gu Y., et al. The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. JCancer Res Clin Oncol 2012, 138:1057-1062.
37. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. JCancer 2011, 2:363-368.
38. Zhu Y., Zhang H., Li Y., Bai J., Liu L., Liu Y., et al. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunol Immunother 2013, 62:1629-1635.
39. Liu Q., Wang Y., Wang H., Liu Y., Liu T., Kunda P.E. Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. JCancer Res Clin Oncol 2013, 139:1357-1372.
40. Dai C.L., Liang Y.J., Wang Y.S., Tiwari A.K., Yan Y.Y., Wang F., et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009, 279:74-83.
41. Wongkajornsilp A., Wamanuttajinda V., Kasetsinsombat K., Duangsa-Ard S., Sa-Ngiamsuntorn K., Hongeng S., et al. Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3(+)CD56(+) Subset through the Co-Culturing Dendritic Cells. PLoS One 2013, 8:e78980.
42. Lu P.H., Negrin R.S. Anovel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. JImmunol 1994, 153:1687-1696.
43. Rossjohn J., Pellicci D.G., Patel O., Gapin L., Godfrey D.I. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol 2012, 12:845-857.
44. Linn Y.C., Lau S.K., Liu B.H., Ng L.H., Yong H.X., Hui K.M. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2009, 126:423-435.
45. Baitsch L., Baumgaertner P., Devevre E., Raghav S.K., Legat A., Barba L., et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. JClin Invest 2011, 121:2350-2360.
46. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. JImmunol Methods 2004, 294:15-22.
47. Saga K., Tamai K., Yamazaki T., Kaneda Y. Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-gamma production. Clin Cancer Res 2013, 19:668-679.
48. Al-Banna N.A., Vaci M., Slauenwhite D., Johnston B., Issekutz T.B. CCR4 and CXCR3 play different roles in the migration of T cells to inflammation in skin, arthritic joints and lymph nodes. Eur J Immunol 2014, 44:1633-1643.
49. Marin V., Dander E., Biagi E., Introna M., Fazio G., Biondi A., et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol 2006, 34:1219-1229.
50. Fagin U., Pitann S., Gross W.L., Lamprecht P. Increased frequency of CCR4+ and CCR6+ memory T-cells including CCR7+CD45RAmed very early memory cells in granulomatosis with polyangiitis (Wegener's). Arthritis Res Ther 2012, 14:R73.